Literature DB >> 19470989

Acid-suppressive medication use and the risk for hospital-acquired pneumonia.

Shoshana J Herzig1, Michael D Howell, Long H Ngo, Edward R Marcantonio.   

Abstract

CONTEXT: The use of acid-suppressive medication has been steadily increasing, particularly in the inpatient setting, despite lack of an accepted indication in the majority of these patients.
OBJECTIVE: To examine the association between acid-suppressive medication and hospital-acquired pneumonia. DESIGN, SETTING, AND PATIENTS: Prospective pharmacoepidemiologic cohort study. All patients who were admitted to a large, urban, academic medical center in Boston, Massachusetts, from January 2004 through December 2007; at least 18 years of age; and hospitalized for 3 or more days were eligible for inclusion. Admissions with time spent in the intensive care unit were excluded. Acid-suppressive medication use was defined as any order for a proton-pump inhibitor or histamine(2) receptor antagonist. Traditional and propensity-matched multivariable logistic regression were used to control for confounders. MAIN OUTCOME MEASURE: Incidence of hospital-acquired pneumonia, defined via codes from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), in patients exposed and unexposed to acid-suppressive medication.
RESULTS: The final cohort comprised 63 878 admissions. Acid-suppressive medication was ordered in 52% of admissions and hospital-acquired pneumonia occurred in 2219 admissions (3.5%). The unadjusted incidence of hospital-acquired pneumonia was higher in the group exposed to acid-suppressive medication than in the unexposed group (4.9% vs 2.0%; odds ratio [OR], 2.6; 95% confidence interval [CI], 2.3-2.8). Using multivariable logistic regression, the adjusted OR of hospital-acquired pneumonia in the group exposed to acid-suppressive medication was 1.3 (95% CI, 1.1-1.4). The matched propensity-score analyses yielded identical results. The association was significant for proton-pump inhibitors (OR, 1.3; 95% CI, 1.1-1.4) but not for histamine(2) receptor antagonists (OR, 1.2; 95% CI, 0.98-1.4).
CONCLUSIONS: In this large, hospital-based pharmacoepidemiologic cohort, acid-suppressive medication use was associated with 30% increased odds of hospital-acquired pneumonia. In subset analyses, statistically significant risk was demonstrated only for proton-pump inhibitor use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470989     DOI: 10.1001/jama.2009.722

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  116 in total

Review 1.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

2.  An analytical approach to characterize morbidity profile dissimilarity between distinct cohorts using electronic medical records.

Authors:  Jonathan S Schildcrout; Melissa A Basford; Jill M Pulley; Daniel R Masys; Dan M Roden; Deede Wang; Christopher G Chute; Iftikhar J Kullo; David Carrell; Peggy Peissig; Abel Kho; Joshua C Denny
Journal:  J Biomed Inform       Date:  2010-08-03       Impact factor: 6.317

3.  Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice.

Authors:  Patrick S Yachimski; Elizabeth A Farrell; Daniel P Hunt; Andrea E Reid
Journal:  Arch Intern Med       Date:  2010-05-10

4.  The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.

Authors:  Maria Meli; Maria Pia Raffa; Renato Malta; Ilaria Morreale; Luigi Aprea; Natale D'Alessandro
Journal:  Int J Clin Pharm       Date:  2015-08-30

5.  Reconsidering a Common Practice: In-Hospital Use of PPIs.

Authors:  Shoshana J Herzig; Robert J Nardino
Journal:  J Gen Intern Med       Date:  2016-04       Impact factor: 5.128

Review 6.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

Review 7.  Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs.

Authors:  Amine Benmassaoud; Emily G McDonald; Todd C Lee
Journal:  CMAJ       Date:  2015-11-23       Impact factor: 8.262

8.  A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers.

Authors:  Sandy H Pang; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

9.  Proton-pump inhibitor use is associated with low serum magnesium concentrations.

Authors:  John Danziger; Jeffrey H William; Daniel J Scott; Joon Lee; Li-wei Lehman; Roger G Mark; Michael D Howell; Leo A Celi; Kenneth J Mukamal
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

Review 10.  Quality improvement in gastroenterology clinical practice.

Authors:  Rakhi Kheraj; Sumeet K Tewani; Gyanprakash Ketwaroo; Daniel A Leffler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.